Addex Therapeutics (ADXN) Registration Filing summary

Company overview and business model

• Clinical-stage pharmaceutical company developing novel orally available small molecule drug candidates for unmet medical needs, including post-stroke recovery, traumatic brain injury, substance use disorders, and chronic cough.

• Holds a 20% equity interest in Neurosterix US Holdings LLC, a spin-out focused on preclinical drug candidates for schizophrenia, mood disorders, and cognition.

• Lead compound dipraglurant is under evaluation for post-stroke/TBI recovery, with a recent collaboration for exclusive IP licensing and research with Sinntaxis AB.

• Other programs include ADX71149 (mGlu2 PAM) and GABAB PAMs for substance use disorder (partnered with Indivior) and chronic cough (internal program).

• Divested discovery platform and early-stage programs to Neurosterix, receiving CHF 5.0 million and retaining a service agreement for key staff support.

Financial performance and metrics

• As of June 30, 2025, cash and cash equivalents were CHF 2.3 million (actual) and CHF 2.74 million (as adjusted for treasury share sales).

• Shareholders' equity as of June 30, 2025, was CHF 7.2 million (actual) and CHF 7.65 million (as adjusted).

• 147,726,315 shares outstanding as of October 31, 2025, with significant treasury shares and shares reserved for warrants and equity incentive plans.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used to advance proprietary drug candidates, including dipraglurant, ADX71149, and GABAB PAM for chronic cough.

• Additional proceeds may support corporate development, partnerships, and grant-funded programs, with interim investment in investment-grade securities.